FDA Intervenes With Anti-Diarrhea Drug Packaging

To encourage proper dosage, the FDA is working with manufacturers to use single dose packaging for anti-diarrhea drugs.

Imodium / Image: HealthDay
Imodium / Image: HealthDay

According to a recent FDA MedWatch article, the FDA has been inundated with reports of serious heart problems and deaths linked to people taking higher than recommended doses of loperamide. More commonly known as Imodium, loperamide is an anti-diarrhea medication that acts on opioid receptors in the intestines to decrease the number of bowel movements. Apparently consumers are intentionally taking much more than the recommended dosage.

The FDA’s maximum approved daily dose for adults is 8 mg per day, but when more is taken it can lead to heart rhythm issues or even death. To prevent this, the FDA is working with manufacturers to implement the use of blister packs and other single dose packaging to minimize the number of doses in each package.

Fresh from the show floor: pharma packaging innovations for 2026
Serialization mandates. Containment demands. Sterile barrier requirements. Our editors found the pharma packaging innovations addressing your biggest challenges at PACK EXPO Las Vegas. Get your free curated report now.
GET YOUR COPY
Fresh from the show floor: pharma packaging innovations for 2026